Loading...
Loading...
AstraZeneca PLC AZN was a big mover last session with shares rising nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading way above the past one month's volatile price range of $62.45 to $65.69.
This drug manufacturing company has seen a mixed track record when it comes to estimate revisions of 1 increase and 1 decrease over the last 30 days. Meanwhile, the Zacks Consensus Estimate has remained unchanged over the same period. Yesterday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
AstraZeneca currently bears a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Better-ranked Pharmaceutical stocks worth considering include AbbVie Inc. ABBV, Allergan Inc. AGN and Johnson & Johnson JNJ. All three stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
This drug manufacturing company has seen a mixed track record when it comes to estimate revisions of 1 increase and 1 decrease over the last 30 days. Meanwhile, the Zacks Consensus Estimate has remained unchanged over the same period. Yesterday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
AstraZeneca currently bears a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Better-ranked Pharmaceutical stocks worth considering include AbbVie Inc. ABBV, Allergan Inc. AGN and Johnson & Johnson JNJ. All three stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ALLERGAN INC AGN: Free Stock Analysis Report
ASTRAZENECA PLC AZN: Free Stock Analysis Report
JOHNSON & JOHNS JNJ: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in